KR100779207B1 - N-(인돌카르보닐-)피페라진 유도체 - Google Patents

N-(인돌카르보닐-)피페라진 유도체 Download PDF

Info

Publication number
KR100779207B1
KR100779207B1 KR1020027000315A KR20027000315A KR100779207B1 KR 100779207 B1 KR100779207 B1 KR 100779207B1 KR 1020027000315 A KR1020027000315 A KR 1020027000315A KR 20027000315 A KR20027000315 A KR 20027000315A KR 100779207 B1 KR100779207 B1 KR 100779207B1
Authority
KR
South Korea
Prior art keywords
formula
compound
indol
methanone
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027000315A
Other languages
English (en)
Korean (ko)
Other versions
KR20020019513A (ko
Inventor
뵈트헤르헨닝
그라이너하르트무트
하르팅유르겐
바르토스지크게르트
자이프리트크리스토프
판암스텔담크리스토프
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20020019513A publication Critical patent/KR20020019513A/ko
Application granted granted Critical
Publication of KR100779207B1 publication Critical patent/KR100779207B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
KR1020027000315A 1999-07-22 2000-07-07 N-(인돌카르보닐-)피페라진 유도체 Expired - Fee Related KR100779207B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19934433.7 1999-07-22
DE19934433A DE19934433A1 (de) 1999-07-22 1999-07-22 N-(Indolcarbonyl-)piperazinderivate

Publications (2)

Publication Number Publication Date
KR20020019513A KR20020019513A (ko) 2002-03-12
KR100779207B1 true KR100779207B1 (ko) 2007-11-27

Family

ID=7915702

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027000315A Expired - Fee Related KR100779207B1 (ko) 1999-07-22 2000-07-07 N-(인돌카르보닐-)피페라진 유도체

Country Status (26)

Country Link
US (2) US6838461B1 (cg-RX-API-DMAC10.html)
EP (1) EP1198453B9 (cg-RX-API-DMAC10.html)
JP (2) JP5242871B2 (cg-RX-API-DMAC10.html)
KR (1) KR100779207B1 (cg-RX-API-DMAC10.html)
CN (1) CN1229345C (cg-RX-API-DMAC10.html)
AR (1) AR024819A1 (cg-RX-API-DMAC10.html)
AT (1) ATE236877T1 (cg-RX-API-DMAC10.html)
AU (1) AU770411B2 (cg-RX-API-DMAC10.html)
BR (1) BR0012607A (cg-RX-API-DMAC10.html)
CA (1) CA2383779C (cg-RX-API-DMAC10.html)
CZ (1) CZ300510B6 (cg-RX-API-DMAC10.html)
DE (2) DE19934433A1 (cg-RX-API-DMAC10.html)
DK (1) DK1198453T5 (cg-RX-API-DMAC10.html)
ES (1) ES2192535T3 (cg-RX-API-DMAC10.html)
HK (1) HK1048636B (cg-RX-API-DMAC10.html)
HU (1) HUP0201988A3 (cg-RX-API-DMAC10.html)
MX (1) MXPA02000730A (cg-RX-API-DMAC10.html)
MY (1) MY122531A (cg-RX-API-DMAC10.html)
NO (1) NO322154B1 (cg-RX-API-DMAC10.html)
PL (1) PL201893B1 (cg-RX-API-DMAC10.html)
PT (1) PT1198453E (cg-RX-API-DMAC10.html)
RU (1) RU2251548C2 (cg-RX-API-DMAC10.html)
SK (1) SK286066B6 (cg-RX-API-DMAC10.html)
UA (1) UA73518C2 (cg-RX-API-DMAC10.html)
WO (1) WO2001007435A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200201486B (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
IL146309A (en) 1999-05-21 2008-03-20 Scios Inc Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38
DE19934432A1 (de) * 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
US20020156453A1 (en) * 1999-10-14 2002-10-24 Pettis Ronald J. Method and device for reducing therapeutic dosage
US20020095134A1 (en) * 1999-10-14 2002-07-18 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
DE10102053A1 (de) * 2001-01-17 2002-07-18 Merck Patent Gmbh Piperazinylcarbonylchinoline und -isochinoline
MXPA03011638A (es) * 2001-06-15 2004-04-02 Hoffmann La Roche Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
DE10157673A1 (de) * 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten
GB0203811D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
DE10212564B4 (de) * 2002-03-12 2007-04-19 Neurobiotec Gmbh 1-Allyl-ergotalkaloid-Derivate und ihre Verwendung zur Prophylaxe und Therapie von Migräne
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
EP1539241A2 (en) * 2002-08-30 2005-06-15 Becton, Dickinson and Company Method of controlling pharmacokinetics of immunomodulatory compounds
DE10246357A1 (de) * 2002-10-04 2004-04-15 Merck Patent Gmbh Verwendung von 5-HT2Rezeptorantagonisten
WO2005016401A2 (en) * 2003-06-13 2005-02-24 Becton Dickinson And Company Improved intra-dermal delivery of biologically active agents
WO2005023328A2 (en) * 2003-08-26 2005-03-17 Becton Dickinson And Company Methods for intradermal delivery of therapeutics agents
WO2005091922A2 (en) * 2004-03-03 2005-10-06 Becton, Dickinson And Company Methods and devices for improving delivery of a substance to skin
CN101022806A (zh) * 2004-04-15 2007-08-22 萨马里坦药品公司 (4-烷基哌嗪基)(苯基)甲酮在治疗阿尔茨海默病中的应用
WO2005115360A2 (en) * 2004-05-11 2005-12-08 Becton, Dickinson And Company Formulations of anti-pain agents and methods of using the same
DE102004047517A1 (de) * 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
CN101119965B (zh) * 2004-12-21 2012-09-26 弗·哈夫曼-拉罗切有限公司 萘满和茚满衍生物及其用途
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
CA2652215A1 (en) * 2006-05-05 2007-11-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate
US7514433B2 (en) * 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
CA2686926C (en) 2007-05-14 2016-01-05 Sk Holdings Co., Ltd. Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
EP2008656A1 (en) * 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia
ES2421237T7 (es) * 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
KR101062376B1 (ko) * 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
US9308323B2 (en) 2011-11-15 2016-04-12 Smiths Medical Asd, Inc. Systems and methods for illuminated medical tubing detection and management indicating a characteristic of at least one infusion pump
RU2549963C1 (ru) * 2014-04-08 2015-05-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дальневосточный государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО "ДВГМУ" Минздрава России) Способ прогнозирования развития критической печеночной недостаточности на основании сывороточного уровня селена
JP6971999B2 (ja) 2016-02-25 2021-11-24 エースニューロン・ソシエテ・アノニム ピペラジン誘導体の酸付加塩
GB2554371B (en) * 2016-09-22 2019-10-09 Resolute Energy Solutions Ltd Well apparatus and associated methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320983A2 (en) * 1987-12-17 1989-06-21 Merrell Dow Pharmaceuticals Inc. Piperidinyl compounds
EP0599240A1 (en) * 1992-11-24 1994-06-01 Hoechst-Roussel Pharmaceuticals Incorporated Indole-7-carboxamide derivatives as analgesics
WO1999011641A1 (en) * 1997-09-03 1999-03-11 Merck Sharp & Dohme Limited Phenylindole derivatives as 5-ht2a receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101601B (fi) 1987-09-24 1998-07-31 Jencap Res Ltd Ehkäisyvalmiste sekä estrogeenin ja progestiinin käyttö ehkäisyvalmist een valmistusmenetelmässä
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
ZA954689B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
WO1998006715A1 (en) 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
DE19934432A1 (de) * 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
JPWO2005099240A1 (ja) * 2004-04-07 2008-03-06 松下電器産業株式会社 情報交換支援装置、情報交換支援方法、及び情報交換支援プログラム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320983A2 (en) * 1987-12-17 1989-06-21 Merrell Dow Pharmaceuticals Inc. Piperidinyl compounds
EP0599240A1 (en) * 1992-11-24 1994-06-01 Hoechst-Roussel Pharmaceuticals Incorporated Indole-7-carboxamide derivatives as analgesics
WO1999011641A1 (en) * 1997-09-03 1999-03-11 Merck Sharp & Dohme Limited Phenylindole derivatives as 5-ht2a receptor antagonists

Also Published As

Publication number Publication date
WO2001007435A3 (de) 2001-08-16
PL201893B1 (pl) 2009-05-29
JP2003505458A (ja) 2003-02-12
PT1198453E (pt) 2003-08-29
CN1364157A (zh) 2002-08-14
KR20020019513A (ko) 2002-03-12
AU6270400A (en) 2001-02-13
DK1198453T3 (da) 2003-07-21
NO20020307D0 (no) 2002-01-21
AR024819A1 (es) 2002-10-23
US20050096330A1 (en) 2005-05-05
HUP0201988A2 (hu) 2002-11-28
UA73518C2 (en) 2005-08-15
CN1229345C (zh) 2005-11-30
EP1198453B9 (de) 2004-11-10
CA2383779C (en) 2011-03-29
WO2001007435A2 (de) 2001-02-01
RU2251548C2 (ru) 2005-05-10
CA2383779A1 (en) 2001-02-01
CZ300510B6 (cs) 2009-06-03
EP1198453A2 (de) 2002-04-24
US7084143B2 (en) 2006-08-01
AU770411B2 (en) 2004-02-19
HUP0201988A3 (en) 2003-12-29
ES2192535T3 (es) 2003-10-16
CZ200268A3 (cs) 2002-04-17
MXPA02000730A (es) 2002-08-20
ZA200201486B (en) 2003-07-30
BR0012607A (pt) 2002-04-09
SK286066B6 (sk) 2008-02-05
NO322154B1 (no) 2006-08-21
MY122531A (en) 2006-04-29
ATE236877T1 (de) 2003-04-15
SK512002A3 (en) 2002-05-09
DK1198453T5 (da) 2005-01-31
JP5242871B2 (ja) 2013-07-24
DE50001729D1 (de) 2003-05-15
NO20020307L (no) 2002-03-21
PL353446A1 (en) 2003-11-17
DE19934433A1 (de) 2001-01-25
US6838461B1 (en) 2005-01-04
JP2012006940A (ja) 2012-01-12
EP1198453B1 (de) 2003-04-09
HK1048636B (zh) 2006-08-11
HK1048636A1 (en) 2003-04-11

Similar Documents

Publication Publication Date Title
CA2383779C (en) N-(indolecarbonyl)piperazine derivatives
KR20020073492A (ko) 5-ht2a 수용체 길항제로 작용하는 피페리딘 및피페라진 유도체
KR100756506B1 (ko) 인돌 유도체
KR100854481B1 (ko) 피페라진일카르보닐퀴놀린 및 ­이소퀴놀린
KR20020027502A (ko) 피페리딘 알콜
KR20010112231A (ko) 5―ht 재흡수 저해제 및 5―ht1b/1d리간드로서의 아미드 및 우레아 유도체

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20101118

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111120

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111120

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000